Rhenman & Partners Asset Management AB Acquires 13,250 Shares of Krystal Biotech, Inc. $KRYS

Rhenman & Partners Asset Management AB lifted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 112.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,000 shares of the company’s stock after acquiring an additional 13,250 shares during the quarter. Rhenman & Partners Asset Management AB owned approximately 0.09% of Krystal Biotech worth $6,164,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Castleark Management LLC bought a new stake in Krystal Biotech in the 4th quarter valued at $7,214,000. Orion Porfolio Solutions LLC bought a new stake in Krystal Biotech in the 4th quarter valued at $228,000. Cibc World Markets Corp bought a new stake in Krystal Biotech in the 4th quarter valued at $404,000. State Board of Administration of Florida Retirement System boosted its stake in Krystal Biotech by 172.4% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 15,756 shares of the company’s stock valued at $3,884,000 after purchasing an additional 9,971 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in Krystal Biotech in the 4th quarter valued at $814,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $317.97 on Friday. The stock has a fifty day moving average price of $288.44 and a 200-day moving average price of $267.89. The company has a market cap of $9.37 billion, a price-to-earnings ratio of 42.51 and a beta of 0.53. Krystal Biotech, Inc. has a fifty-two week low of $127.99 and a fifty-two week high of $331.49.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The firm had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Research analysts predict that Krystal Biotech, Inc. will post 7.83 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total transaction of $193,903.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the sale, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on KRYS. Jefferies Financial Group boosted their price target on Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Guggenheim boosted their price target on Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Evercore reiterated an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Citigroup upped their target price on Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Finally, Wolfe Research began coverage on Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating for the company. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Krystal Biotech presently has an average rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.